引用本文:郭 瑜,黄东辉,蔡伟霞.阿昔洛韦联合脾氨肽治疗儿童传染性单核细胞增多症的临床疗效观察[J].中国临床新医学,2018,11(8):765-768.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2079次   下载 1664 本文二维码信息
码上扫一扫!
分享到: 微信 更多
阿昔洛韦联合脾氨肽治疗儿童传染性单核细胞增多症的临床疗效观察
郭 瑜,黄东辉,蔡伟霞
523523 广东,东莞市桥头医院儿科
摘要:
[摘要] 目的 探讨阿昔洛韦抗病毒联合脾氨肽(脾氨肽口服冻干粉)免疫调节剂治疗儿童传染性单核细胞增多症(IM)的有效性。方法 选取2015-08~2017-05在该院住院的IM患儿56例,随机分为两组各28例,对照组给予阿昔洛韦抗病毒及对症等常规治疗;观察组在对照组的基础上加用细胞免疫调节剂脾氨肽治疗,疗程2周。观察两组患儿临床疗效、临床症状改善情况以及T淋巴细胞亚群的变化情况。结果 观察组临床疗效优于对照组,差异有统计学学意义(P<0.05),但观察组临床症状、体征消退时间以及住院时间较对照组短(P均<0.05),治疗后两组患儿CD3+细胞水平、CD8+细胞水平降低,CD4+细胞水平及CD4+/CD8+明显升高,差异有统计学意义(P<0.05),且观察组变化水平更显著(P<0.05)。结论 阿昔洛韦联合脾氨肽治疗IM的临床疗效优于单纯使用阿昔洛韦,临床疗效显著及安全性更好,值得基层临床推广应用。
关键词:  传染性单核细胞增多症  T淋巴细胞亚群  阿昔洛韦  脾氨肽  细胞免疫调节剂
DOI:10.3969/j.issn.1674-3806.2018.08.09
分类号:R 725.1
基金项目:东莞市社会科技发展(一般)项目(编号:201750715036255)
Clinical study of acyclovir combined with spleen aminopeptide on infectious mononucleosis in children
GUO Yu, HUANG Dong-hui, CAI Wei-xia
Department of Paediatrics, Qiaotou Hospital of Dongguan City, Guangdong 523523, China
Abstract:
[Abstract] Objective To investigate the clinical study of acyclovir combined with spleen aminopeptide(oral freeze-dried powder) immunomodulator on infectious mononucleosis(IM) in children. Methods 56 patients with IM were randomly divided into two groups, with 28 cases in each group. The control group was treated with acyclovir for antivirus and symptomatic treatment for 2 weeks. The observation group was treated with a cellular immunomodulator spleen aminopeptide plus the same treatment as the control group. The clinical effect, improvement of clinical symptoms and the changes of T lymphocyte subsets were compared between the two groups. Results The clinical effect of the observation group was better than that of the control group(P<0.05). The time for improvement of the clinical symptoms and the signs recovery time, and the time for hospital stay in the observation group was significantly shorter than that in the control group(P<0.05). Compared with those before treatment, the levels of CD3+ cells and CD8+ cells were significantly lower and the levels of CD4+ cells and CD4+/ CD8+ were significantly higher in both of the two groups after treatment(P<0.05), however the improvements of these indexes in the observation group were better than those in the control group(P<0.05). Conclusion Acyclovir combined with spleen aminopeptide is safer and more effective than acyclovir alone in treatment of IM in children.
Key words:  Infectious mononucleosis  T lymphocyte subsets  Acyclovir  Spleen aminopeptide  Cell immunomodulator